View Financial HealthCodeLab Capital 配当と自社株買い配当金 基準チェック /06CodeLab Capital配当金を支払った記録がありません。主要情報n/a配当利回り-32.8%バイバック利回り総株主利回り-32.8%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 01CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor.CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026.Reported Earnings • Apr 24Full year 2025 earnings releasedFull year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024).New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (kr40.5m market cap, or US$4.21m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Dec 30CodeLab Capital AS, Annual General Meeting, Jun 23, 2026CodeLab Capital AS, Annual General Meeting, Jun 23, 2026.お知らせ • Dec 29+ 4 more updatesCodeLab Capital AS to Report Fiscal Year 2025 Final Results on Apr 21, 2026CodeLab Capital AS announced that they will report fiscal year 2025 final results at 4:25 PM, Central European Standard Time on Apr 21, 2026お知らせ • May 28CodeLab Capital AS announced that it has received fundingCodeLab Capital AS announced a private placement transaction and it has issued 4799998 new shares on May 26, 2025.New Risk • May 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr70m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr70m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Revenue is less than US$1m (kr271k revenue, or US$27k). Market cap is less than US$10m (kr18.9m market cap, or US$1.85m).お知らせ • May 06CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million.CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million on May 5, 2025. The purchase price is NOK 20 million, to be paid as follows: one third of the purchase price shall be paid in cash at closing of the Transaction, one third of the purchase price shall be paid in kind through the issuance of 1,302,071 consideration shares in CodeLab at Closing, valued at NOK 5.12 per share, one third of the purchase price shall be deferred payment which falls due first quarter of 2028. The deferred payment is subject to adjustment depending on the development of the cash EBITDA of Kuba for 2027, but is capped at 1.5x the original deferred payment. Following the acquisition of Kuba Norge AS, CodeLab Capital AS is adjusting its leadership structure to align with its strategic direction. CEO Kristian Ikast will transition to the role of Chairman of the Board of Directors and continue as a close advisor to the company. CFO Christoffer Mathiesen will remain in his current role. Anton Lorenz Bondesen, the current Chairman of the Board, will become the CEO and will also continue as a member of the Board of Directors. The Transaction is subject to standard closing conditions, including the approval of the Company's shareholders in a general meeting for issuance of the Consideration Shares as well as certain other amendments to the share capital of the Company as described below. CodeLab Capital AS has secured approximately NOK 13.9 million in new equity funding for its acquisition of Kuba Norge AS, with contributions from leading shareholders such as Lorenz AS and Codee Holding AS, as well as other existing shareholders and external investors, including the sellers. The funding is at a subscription price of NOK 3.00 per share. CodeLab plans to conduct a private placement to complete the transaction, with a potential subsequent repair issue for minority shareholders. For the period ending December 31, 2024, Kuba Norge As reported total revenue of NOK 12.5 million. Advokatfirmaet Schjødt As acted as legal advisor to CodeLab Capital AS.New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). High level of non-cash earnings (114% accrual ratio). Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (kr2.9m revenue, or US$274k). Market cap is less than US$10m (kr21.8m market cap, or US$2.07m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).Recent Insider Transactions • Mar 05Insider recently bought kr62k worth of stockOn the 3rd of March, Anton Bondesen bought around 1m shares on-market at roughly kr0.062 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr1.1m. Insiders have collectively bought kr6.1m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Feb 01Chairman of the Board recently bought kr1.1m worth of stockOn the 27th of January, Jesper Ganc-Petersen bought around 26m shares on-market at roughly kr0.044 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jesper has been a buyer over the last 12 months, purchasing a net total of kr6.2m worth in shares.お知らせ • Jan 24CodeLab Capital AS to Report Fiscal Year 2024 Results on May 15, 2025CodeLab Capital AS announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on May 15, 2025お知らせ • Jan 02CodeLab Capital AS, Annual General Meeting, Jun 27, 2025CodeLab Capital AS, Annual General Meeting, Jun 27, 2025.お知らせ • Jan 01+ 1 more updateCodeLab Capital AS to Report Q4, 2025 Results on Feb 20, 2026CodeLab Capital AS announced that they will report Q4, 2025 results on Feb 20, 2026New Risk • Sep 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 114% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (114% accrual ratio). Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (kr2.9m revenue, or US$272k). Market cap is less than US$10m (kr95.4m market cap, or US$9.00m).New Risk • Aug 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 72% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (kr47m revenue, or US$4.4m). Market cap is less than US$100m (kr112.8m market cap, or US$10.4m).Recent Insider Transactions • Jul 26Chairman of the Board recently bought kr5.0m worth of stockOn the 22nd of July, Jesper Ganc-Petersen bought around 17m shares on-market at roughly kr0.30 per share. This transaction increased Jesper's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jesper's only on-market trade for the last 12 months.お知らせ • Jul 24Uniscale, Wholly-Owned Subsidiary of CodeLab Capital, Announces Peter Tuborgh Arnth Nielsen as New Head of Enterprise and PartnershipsUniscale, a wholly-owned subsidiary of CodeLab Capital, announced Peter Tuborgh Arnth Nielsen as the new Head of Enterprise and Partnerships, effective immediately. His role will be crucial in ensuring the growth and development of these strategically important areas of the business. Peter brings extensive experience in building long-term partnerships with international enterprises and large customers.New Risk • Jun 16New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: kr47m (US$4.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (kr97.9m market cap, or US$9.17m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Revenue is less than US$5m (kr47m revenue, or US$4.4m).New Risk • Jun 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr99.1m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average weekly change). Earnings have declined by 50% per year over the past 5 years. Market cap is less than US$10m (kr99.1m market cap, or US$9.38m). Minor Risk Shareholders have been diluted in the past year (2.5% increase in shares outstanding).New Risk • Apr 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (61% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (kr163.1m market cap, or US$14.8m).New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Share price has been highly volatile over the past 3 months (61% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (kr212.8m market cap, or US$20.0m).New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (kr59.7m market cap, or US$5.73m).New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr104.2m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (kr104.2m market cap, or US$9.65m).お知らせ • Oct 28CodeLab Capital AS to Report Q4, 2023 Results on Feb 23, 2024CodeLab Capital AS announced that they will report Q4, 2023 results on Feb 23, 2024Reported Earnings • Aug 31First half 2023 earnings releasedFirst half 2023 results: Revenue: kr91.0m (down 7.2% from 1H 2022). Net loss: kr45.8m (loss narrowed 26% from 1H 2022).New Risk • Jun 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr184m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr184m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue has declined by 6.7% over the past year. Market cap is less than US$10m (kr79.3m market cap, or US$7.36m).お知らせ • May 19Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS.Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS on May 17, 2023.Jesper Melin Ganc-Petersen completed the acquisition of an unknown minority stake in PatientSky Group AS on May 17, 2023.Buying Opportunity • May 03Now 81% undervalued after recent price dropOver the last 90 days, the stock is down 60%. The fair value is estimated to be kr2.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is forecast to grow by 36% per annum over the same time period.Reported Earnings • Mar 06Full year 2022 earnings releasedFull year 2022 results: Revenue: kr194.5m (down 6.8% from FY 2021). Net loss: kr121.3m (loss widened 32% from FY 2021). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe.お知らせ • Jan 03+ 4 more updatesPatientSky Group AS to Report Q1, 2023 Results on May 25, 2023PatientSky Group AS announced that they will report Q1, 2023 results on May 25, 2023Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 10.0% from 3Q 2021). Net loss: kr29.3m (loss widened 69% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Healthcare Services industry in Norway.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Investment Director & Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 11% from 3Q 2021). Net loss: kr29.3m (loss widened 5.1% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Healthcare Services industry in Norway.Reported Earnings • Aug 29Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr48.0m (down 6.7% from 2Q 2021). Net loss: kr22.9m (loss widened 26% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.5% compared to a 26% growth forecast for the Healthcare Services industry in Norway.Buying Opportunity • Jul 02Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be kr3.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last year. Earnings per share has declined by 291%. For the next 3 years, revenue is forecast to decline by 2.4% per annum. Earnings is forecast to grow by 24% per annum over the same time period.Price Target Changed • Apr 27Price target decreased to kr5.00Down from kr7.00, the current price target is provided by 1 analyst. New target price is 78% above last closing price of kr2.81. Stock is down 74% over the past year.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 24Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: kr210.0m (up 50% from FY 2020). Net loss: kr79.4m (loss widened 239% from FY 2020). Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 14%, compared to a 46% growth forecast for the industry in Norway.Recent Insider Transactions • Sep 03Chief Commercial Officer recently bought kr575k worth of stockOn the 1st of September, Egil Noen bought around 150k shares on-market at roughly kr3.84 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr505k more in shares than they bought in the last 12 months.Major Estimate Revision • Jul 15Consensus EPS estimates fall to -kr0.30The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from kr217.5m to kr206.0m. Losses expected to increase from -kr0.26 to -kr0.30. Healthcare Services industry in Norway expected to see average net income growth of 22% next year. Consensus price target down from kr11.00 to kr7.00. Share price fell 10% to kr4.50 over the past week.Is New 90 Day High Low • Feb 17New 90-day low: kr11.81The company is down 8.0% from its price of kr12.90 on 19 November 2020. The Norwegian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 12% over the same period.Recent Insider Transactions • Jan 30Co-founder & CTO recently sold kr1.1m worth of stockOn the 27th of January, Andreas Kruger sold around 80k shares on-market at roughly kr13.45 per share. This was the largest sale by an insider in the last 3 months. This was Andreas' only on-market trade for the last 12 months.決済の安定と成長配当データの取得安定した配当: CODEの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CODEの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場CodeLab Capital 配当利回り対市場CODE 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CODE)n/a市場下位25% (NO)3.1%市場トップ25% (NO)7.4%業界平均 (Healthcare Services)1.8%アナリスト予想 (CODE) (最長3年)n/a注目すべき配当: CODEは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CODEは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CODEの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CODEが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YNO 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 09:04終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CodeLab Capital AS 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kristian StøleCarnegie Investment Bank ABOle-Andreas KrohnDNB CarnegieEmilie EngenDNB Carnegie
お知らせ • May 01CodeLab Capital AS announced that it expects to receive NOK 18.8 million in funding from Agil Helse AS and other investor.CodeLab Capital AS announced a private placement to issue 4,700,000 common share at an issue price of NOK 4 for the proceeds of NOK 18,800,000 on April 29, 2026. The demand to subscribe for new shares has been received from the Company’s largest shareholders, Agil Helse AS, and new external investors. Investors that have signed the pre-commitment letters will be allocated at least NOK 17,000,000. Any issuance of new shares in the private placement is subject to the approval by the general meeting. Summons to the general meeting is expected to be sent at the latest by May 6,2026.
Reported Earnings • Apr 24Full year 2025 earnings releasedFull year 2025 results: Revenue: kr10.8m (up kr10.6m from FY 2024). Net loss: kr14.9m (loss narrowed 90% from FY 2024).
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 5.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (kr162k revenue, or US$17k). Market cap is less than US$10m (kr40.5m market cap, or US$4.21m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Dec 30CodeLab Capital AS, Annual General Meeting, Jun 23, 2026CodeLab Capital AS, Annual General Meeting, Jun 23, 2026.
お知らせ • Dec 29+ 4 more updatesCodeLab Capital AS to Report Fiscal Year 2025 Final Results on Apr 21, 2026CodeLab Capital AS announced that they will report fiscal year 2025 final results at 4:25 PM, Central European Standard Time on Apr 21, 2026
お知らせ • May 28CodeLab Capital AS announced that it has received fundingCodeLab Capital AS announced a private placement transaction and it has issued 4799998 new shares on May 26, 2025.
New Risk • May 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr70m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr70m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 0.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Revenue is less than US$1m (kr271k revenue, or US$27k). Market cap is less than US$10m (kr18.9m market cap, or US$1.85m).
お知らせ • May 06CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million.CodeLab Capital AS (OB:CODE) signed an agreement to acquire 97.40% stake in Kuba Norge As for NOK 18.5 million on May 5, 2025. The purchase price is NOK 20 million, to be paid as follows: one third of the purchase price shall be paid in cash at closing of the Transaction, one third of the purchase price shall be paid in kind through the issuance of 1,302,071 consideration shares in CodeLab at Closing, valued at NOK 5.12 per share, one third of the purchase price shall be deferred payment which falls due first quarter of 2028. The deferred payment is subject to adjustment depending on the development of the cash EBITDA of Kuba for 2027, but is capped at 1.5x the original deferred payment. Following the acquisition of Kuba Norge AS, CodeLab Capital AS is adjusting its leadership structure to align with its strategic direction. CEO Kristian Ikast will transition to the role of Chairman of the Board of Directors and continue as a close advisor to the company. CFO Christoffer Mathiesen will remain in his current role. Anton Lorenz Bondesen, the current Chairman of the Board, will become the CEO and will also continue as a member of the Board of Directors. The Transaction is subject to standard closing conditions, including the approval of the Company's shareholders in a general meeting for issuance of the Consideration Shares as well as certain other amendments to the share capital of the Company as described below. CodeLab Capital AS has secured approximately NOK 13.9 million in new equity funding for its acquisition of Kuba Norge AS, with contributions from leading shareholders such as Lorenz AS and Codee Holding AS, as well as other existing shareholders and external investors, including the sellers. The funding is at a subscription price of NOK 3.00 per share. CodeLab plans to conduct a private placement to complete the transaction, with a potential subsequent repair issue for minority shareholders. For the period ending December 31, 2024, Kuba Norge As reported total revenue of NOK 12.5 million. Advokatfirmaet Schjødt As acted as legal advisor to CodeLab Capital AS.
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). High level of non-cash earnings (114% accrual ratio). Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (kr2.9m revenue, or US$274k). Market cap is less than US$10m (kr21.8m market cap, or US$2.07m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
Recent Insider Transactions • Mar 05Insider recently bought kr62k worth of stockOn the 3rd of March, Anton Bondesen bought around 1m shares on-market at roughly kr0.062 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr1.1m. Insiders have collectively bought kr6.1m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Feb 01Chairman of the Board recently bought kr1.1m worth of stockOn the 27th of January, Jesper Ganc-Petersen bought around 26m shares on-market at roughly kr0.044 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Jesper has been a buyer over the last 12 months, purchasing a net total of kr6.2m worth in shares.
お知らせ • Jan 24CodeLab Capital AS to Report Fiscal Year 2024 Results on May 15, 2025CodeLab Capital AS announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on May 15, 2025
お知らせ • Jan 02CodeLab Capital AS, Annual General Meeting, Jun 27, 2025CodeLab Capital AS, Annual General Meeting, Jun 27, 2025.
お知らせ • Jan 01+ 1 more updateCodeLab Capital AS to Report Q4, 2025 Results on Feb 20, 2026CodeLab Capital AS announced that they will report Q4, 2025 results on Feb 20, 2026
New Risk • Sep 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 114% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (114% accrual ratio). Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Revenue is less than US$1m (kr2.9m revenue, or US$272k). Market cap is less than US$10m (kr95.4m market cap, or US$9.00m).
New Risk • Aug 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 72% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (kr47m revenue, or US$4.4m). Market cap is less than US$100m (kr112.8m market cap, or US$10.4m).
Recent Insider Transactions • Jul 26Chairman of the Board recently bought kr5.0m worth of stockOn the 22nd of July, Jesper Ganc-Petersen bought around 17m shares on-market at roughly kr0.30 per share. This transaction increased Jesper's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jesper's only on-market trade for the last 12 months.
お知らせ • Jul 24Uniscale, Wholly-Owned Subsidiary of CodeLab Capital, Announces Peter Tuborgh Arnth Nielsen as New Head of Enterprise and PartnershipsUniscale, a wholly-owned subsidiary of CodeLab Capital, announced Peter Tuborgh Arnth Nielsen as the new Head of Enterprise and Partnerships, effective immediately. His role will be crucial in ensuring the growth and development of these strategically important areas of the business. Peter brings extensive experience in building long-term partnerships with international enterprises and large customers.
New Risk • Jun 16New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: kr47m (US$4.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (kr97.9m market cap, or US$9.17m). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Revenue is less than US$5m (kr47m revenue, or US$4.4m).
New Risk • Jun 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr99.1m (US$9.38m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (60% average weekly change). Earnings have declined by 50% per year over the past 5 years. Market cap is less than US$10m (kr99.1m market cap, or US$9.38m). Minor Risk Shareholders have been diluted in the past year (2.5% increase in shares outstanding).
New Risk • Apr 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (61% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (2.5% increase in shares outstanding). Market cap is less than US$100m (kr163.1m market cap, or US$14.8m).
New Risk • Mar 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Share price has been highly volatile over the past 3 months (61% average weekly change). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (kr212.8m market cap, or US$20.0m).
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (kr59.7m market cap, or US$5.73m).
New Risk • Nov 22New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr104.2m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr150m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (kr104.2m market cap, or US$9.65m).
お知らせ • Oct 28CodeLab Capital AS to Report Q4, 2023 Results on Feb 23, 2024CodeLab Capital AS announced that they will report Q4, 2023 results on Feb 23, 2024
Reported Earnings • Aug 31First half 2023 earnings releasedFirst half 2023 results: Revenue: kr91.0m (down 7.2% from 1H 2022). Net loss: kr45.8m (loss narrowed 26% from 1H 2022).
New Risk • Jun 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr184m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr184m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Revenue has declined by 6.7% over the past year. Market cap is less than US$10m (kr79.3m market cap, or US$7.36m).
お知らせ • May 19Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS.Jesper Melin Ganc-Petersen acquired an unknown minority stake in PatientSky Group AS on May 17, 2023.Jesper Melin Ganc-Petersen completed the acquisition of an unknown minority stake in PatientSky Group AS on May 17, 2023.
Buying Opportunity • May 03Now 81% undervalued after recent price dropOver the last 90 days, the stock is down 60%. The fair value is estimated to be kr2.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to decline by 0.7% per annum. Earnings is forecast to grow by 36% per annum over the same time period.
Reported Earnings • Mar 06Full year 2022 earnings releasedFull year 2022 results: Revenue: kr194.5m (down 6.8% from FY 2021). Net loss: kr121.3m (loss widened 32% from FY 2021). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare Services industry in Europe.
お知らせ • Jan 03+ 4 more updatesPatientSky Group AS to Report Q1, 2023 Results on May 25, 2023PatientSky Group AS announced that they will report Q1, 2023 results on May 25, 2023
Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 10.0% from 3Q 2021). Net loss: kr29.3m (loss widened 69% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Healthcare Services industry in Norway.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Investment Director & Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr46.3m (down 11% from 3Q 2021). Net loss: kr29.3m (loss widened 5.1% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Healthcare Services industry in Norway.
Reported Earnings • Aug 29Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr48.0m (down 6.7% from 2Q 2021). Net loss: kr22.9m (loss widened 26% from 2Q 2021). Over the next year, revenue is expected to shrink by 3.5% compared to a 26% growth forecast for the Healthcare Services industry in Norway.
Buying Opportunity • Jul 02Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 11%. The fair value is estimated to be kr3.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 30% over the last year. Earnings per share has declined by 291%. For the next 3 years, revenue is forecast to decline by 2.4% per annum. Earnings is forecast to grow by 24% per annum over the same time period.
Price Target Changed • Apr 27Price target decreased to kr5.00Down from kr7.00, the current price target is provided by 1 analyst. New target price is 78% above last closing price of kr2.81. Stock is down 74% over the past year.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Sven Bakken was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 24Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: kr210.0m (up 50% from FY 2020). Net loss: kr79.4m (loss widened 239% from FY 2020). Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 14%, compared to a 46% growth forecast for the industry in Norway.
Recent Insider Transactions • Sep 03Chief Commercial Officer recently bought kr575k worth of stockOn the 1st of September, Egil Noen bought around 150k shares on-market at roughly kr3.84 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr505k more in shares than they bought in the last 12 months.
Major Estimate Revision • Jul 15Consensus EPS estimates fall to -kr0.30The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from kr217.5m to kr206.0m. Losses expected to increase from -kr0.26 to -kr0.30. Healthcare Services industry in Norway expected to see average net income growth of 22% next year. Consensus price target down from kr11.00 to kr7.00. Share price fell 10% to kr4.50 over the past week.
Is New 90 Day High Low • Feb 17New 90-day low: kr11.81The company is down 8.0% from its price of kr12.90 on 19 November 2020. The Norwegian market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 12% over the same period.
Recent Insider Transactions • Jan 30Co-founder & CTO recently sold kr1.1m worth of stockOn the 27th of January, Andreas Kruger sold around 80k shares on-market at roughly kr13.45 per share. This was the largest sale by an insider in the last 3 months. This was Andreas' only on-market trade for the last 12 months.